Nader Mahmood, MD
Pulmonary Disease · Totowa, NJNPI 1396906913
Payments from drug & device makers
Across 457 payments — averaging $91.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Verona Pharma, Inc.$12K
- GSK$11K
- Sanofi$565
- Amgen$320
- Pulmonx Corporation$289
- plus $3K from 35 others
What the payments were for
- Speaking & faculty fees$29,92572%
- Travel & lodging$9752%
- Food & beverage$10,13424%
- Education$7112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 102 | $14,827 |
| Verona Pharma, Inc. | 26 | $12,003 |
| GSK | 144 | $10,947 |
| Sanofi | 19 | $565 |
| Amgen | 12 | $320 |
| Pulmonx Corporation | 7 | $289 |
| Philips North America LLC | 14 | $257 |
| Mylan Specialty L.p. | 14 | $254 |
| Boehringer Ingelheim | 17 | $238 |
| Insmed, Inc. | 14 | $234 |
| Electromed, Inc. | 19 | $189 |
| Mallinckrodt Hospital Products Inc. | 13 | $184 |
| Sanofi-aventis U.S. LLC | 2 | $139 |
| Intuitive Surgical | 1 | $129 |
| Novartis | 1 | $125 |
| Novo Nordisk | 1 | $120 |
| Ambu Inc. | 1 | $118 |
| Regeneron Healthcare Solutions, Inc. | 8 | $117 |
| Viatris Specialty LLC | 5 | $99 |
| Grifols USA, LLC | 3 | $54 |
| Baxter Healthcare | 3 | $54 |
| AbbVie | 3 | $51 |
| ANI Pharmaceuticals, Inc. | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| United Therapeutics Corporation | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| Merck | 2 | $28 |
| Gilead | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Inogen, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Abiomed | 1 | $20 |
| Inari Medical, Inc. | 1 | $18 |
| 3b Medical, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Resmed Corp | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$12,956
- Ohtuvayre$11,821
- TRELEGY ELLIPTA$8,650
- DUPIXENT$549
- TEZSPIRE$481
- AIRSUPRA$439
- BREZTRI$430
- NUCALA$227
- CHARTIS CATHETER$173
- ZEPHYR DELIVERY CATHETER$173
- ZEPHYR ENDOBRONCHIAL VALVE$173
- PULMONX CHARTIS TABLET CONSOLE$173
- Da Vinci Surgical System$129
- COSENTYX$125
- ANORO ELLIPTA$125
- SYMBICORT$123
- AREXVY$120
- Wegovy$120
- ANORO$118
How this compares
$41,744 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $213,598 |
| TezspireTezepelumab-Ekko | 41 | $178,271 |
| NucalaMepolizumab | 23 | $91,222 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $86,405 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 83 | $84,791 |
| Dupixent PenDupilumab | 14 | $51,316 |
| Pirfenidone | 29 | $25,338 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $18,734 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $13,469 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $10,637 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $8,442 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,899 |
| Arnuity ElliptaFluticasone Furoate | 24 | $5,986 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 136 | $5,029 |
| Fluticasone Propionate | 50 | $1,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere | $14,827 | $263,062124 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $10,947 | $219,882183 claims |
| Boehringer IngelheimOfev | $238 | $213,59817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Totowa
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.